진통제 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the analgesics market size was valued at USD 50.65 billion in 2025 and is estimated to grow from USD 54.29 billion in 2026 to reach USD 76.87 billion by 2031, at a CAGR of 7.20% during the forecast period (2026-2031).

This report is Segmented by Type (Prescription, OTC), Drug Class (Opioids, Nsaids, Acetaminophen, Combination, Local/Topical Analgesics), Route of Administration (Oral, Parenteral, Topical, Transdermal, Rectal), Pain Type (Musculoskeletal, Surgical, Cancer, Neuropathic, Migraine, Dental, Obstetric, Pediatric), Distribution Channel (Hospital, Retail, Online Pharmacies), and Geography. Value (USD).

Global Analgesics Market Trends and Insights

Rising Chronic Pain And Musculoskeletal Burden

Chronic pain, influenced by multiple factors rather than a single disease, is a key driver of the analgesics market. Aging, obesity, sedentary lifestyles, and longer survival after major illnesses are increasing the number of patients requiring ongoing treatment for recurring pain. A 2025 study projected a rise in osteoarthritis cases among adults aged 55 and older through 2050, highlighting sustained demand for musculoskeletal pain therapies. High BMI contributes significantly to osteoarthritis-related disabilities, expanding the patient pool through aging and metabolic risks. This trend supports demand across hospitals, specialty clinics, and retail settings, while boosting the appeal of combination strategies and targeted products for long-term pain management.

Aging-Linked Osteoarthritis And Neuropathic Pain Demand Increase

The analgesics market is experiencing strong demand in regions where aging and metabolic diseases overlap, such as North America, Europe, Japan, South Korea, and urban Asia. The treated population is expanding for both joint and nerve pain. Neuropathic pain, requiring longer treatment and careful adjustments, is projected to be the fastest-growing pain category through 2031. Osteoarthritis continues to maintain a broad patient base, keeping musculoskeletal pain central to market demand. This dual demand from degenerative and neuropathic conditions is driving suppliers to diversify portfolios beyond traditional opioids and basic oral analgesics.

Opioid Misuse Controls And Tighter Prescribing Frameworks

Opioid controls continue to restrict a segment of the analgesics market while creating opportunities for alternatives. The DEA has reduced oxycodone production quotas by over 6% for 2026, marking the tenth consecutive year of quota reductions for key opioids. This tighter supply environment has led to challenges in managing shortages for several Schedule II medicines, including critical hospital pain therapies. Regulatory oversight is also influencing prescriber behavior, making long-term opioid use less sustainable in routine practice. As a result, the market retains a portion of its opioid base but is shifting growth toward safer and more targeted options.

Other drivers and restraints analyzed in the detailed report include:

1. Shift Toward Non-Opioid And Multimodal Pain Care Protocols
2. Online Pharmacy Expansion for OTC Analgesic Access
3. NSAID And Acetaminophen Safety Liabilities

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, prescription analgesics accounted for 67.29% of market revenue, maintaining their leadership in the analgesics market. This dominance reflects the reliance on hospital-based treatments for cancer pain, post-surgical pain, neuropathic pain, and severe musculoskeletal conditions. Prescription use remains essential due to physician oversight, dosage adjustments, and access to specialized products unavailable in self-care channels. The NOPAIN Act's implementation in 2025 further supported reimbursement for non-opioid treatments, ensuring the relevance of prescription pathways despite reduced opioid volumes. OTC analgesics are projected to grow at a CAGR of 8.20% from 2026 to 2031, driven by channel expansion and brand extensions rather than shifts in clinical demand.

Opioids held 54.34% of the drug class segment in 2025, maintaining their leading position despite policy pressures. Their share reflects legacy use in chronic pain, palliative care, post-operative settings, and severe pain episodes where alternatives are insufficient. In regions with limited access, opioids remain critical for addressing unmet palliative care needs. The global imbalance in opioid consumption highlights the challenges of transitioning away from opioids uniformly across markets.

NSAIDs are forecast to grow at a CAGR of 9.10% through 2031, making them the fastest-growing drug class. This growth is driven by their adoption in opioid-sparing regimens and their broad application in musculoskeletal, inflammatory, and post-procedural pain management.

Geography Analysis

In 2025, North America accounted for 41.67% of global revenue, maintaining its position as the largest contributor to the analgesics market. The region benefits from high pharmaceutical spending, strong brand presence, and a significant chronic pain patient base. Policy changes, such as the NOPAIN Act and stricter opioid supply controls, continue to shape the market, ensuring North America's central role in value creation as treatment approaches evolve.

Asia-Pacific is projected to grow at a CAGR of 10.15% through 2031, making it the fastest-growing region in the analgesics market. The region's growth is driven by an increasing chronic disease burden, expanding urban healthcare infrastructure, and improved access to OTC and prescription pain therapies. Haleon's acquisition of the remaining 12% equity in its China OTC joint venture in 2025 highlights the strategic focus on regional execution and market control in this key growth area.

Europe remains a mature yet active market, supported by established healthcare systems and balanced demand for prescription and OTC analgesics. Aging populations, chronic pain prevalence, and reimbursement structures sustain demand, while regulatory changes add dynamism. The Middle East and Africa, though smaller, show potential for gradual growth due to urbanization and capacity building. South America also demonstrates steady demand, driven by aging demographics and the reach of retail pharmacy networks. Together, these regions diversify the analgesics market's growth beyond its primary revenue contributors.

1. Amneal Pharmaceuticals
2. Apotex
3. Assertio Holdings, Inc.
4. Aurobindo Pharma
5. Bayer
6. Cipla
7. Dr. Reddy's Laboratories
8. Fresenius
9. Grunenthal GmbH
10. Haleon plc
11. Hikma Pharmaceuticals
12. Kenvue Inc.
13. Lupin
14. Opella
15. Perrigo Company
16. Purdue Pharma
17. Reckitt Benckiser Group
18. Sun Pharmaceuticals Industries
19. Teva Pharmaceutical Industries
20. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Chronic Pain and Musculoskeletal Burden
  • 4.2.2 Aging-Linked Osteoarthritis and Neuropathic Pain Demand
  • 4.2.3 Shift Toward Non-Opioid and Multimodal Pain Care
  • 4.2.4 Online Pharmacy Expansion for OTC Access
  • 4.2.5 IV Opioid-Sparing Multimodal Post-Operative Protocols
  • 4.2.6 Closing Opioid-Access Gaps in LMIC Palliative Care
• 4.3 Market Restraints
  • 4.3.1 Opioid Misuse Controls and Tighter Prescribing Rules
  • 4.3.2 NSAID and Acetaminophen Safety Liabilities
  • 4.3.3 API Concentration and Asia Supply Dependency
  • 4.3.4 Regulatory Friction in Bioequivalence and Shortage Management
• 4.4 Supply/Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Type
  • 5.1.1 Prescription
  • 5.1.2 Over-the-Counter
• 5.2 By Drug Class
  • 5.2.1 Opioids
  • 5.2.2 NSAIDs
  • 5.2.3 Acetaminophen
  • 5.2.4 Combination Analgesics
  • 5.2.5 Local Anesthetics and Topical Analgesics
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Topical
  • 5.3.4 Transdermal
  • 5.3.5 Rectal
• 5.4 By Pain Type
  • 5.4.1 Musculoskeletal Pain
  • 5.4.2 Surgical and Trauma Pain
  • 5.4.3 Cancer Pain
  • 5.4.4 Neuropathic Pain
  • 5.4.5 Migraine and Headache
  • 5.4.6 Dental and Orofacial Pain
  • 5.4.7 Obstetric and Gynecologic Pain
  • 5.4.8 Pediatric Pain
• 5.5 By Distribution Channel
  • 5.5.1 Hospital Pharmacies
  • 5.5.2 Retail Pharmacies and Drug Stores
  • 5.5.3 Online Pharmacies
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Amneal Pharmaceuticals, Inc.
  • 6.3.2 Apotex Inc.
  • 6.3.3 Assertio Holdings, Inc.
  • 6.3.4 Aurobindo Pharma Limited
  • 6.3.5 Bayer AG
  • 6.3.6 Cipla Limited
  • 6.3.7 Dr. Reddy's Laboratories Ltd.
  • 6.3.8 Fresenius Kabi AG
  • 6.3.9 Grunenthal GmbH
  • 6.3.10 Haleon plc
  • 6.3.11 Hikma Pharmaceuticals PLC
  • 6.3.12 Kenvue Inc.
  • 6.3.13 Lupin Limited
  • 6.3.14 Opella
  • 6.3.15 Perrigo Company plc
  • 6.3.16 Purdue Pharma L.P.
  • 6.3.17 Reckitt Benckiser Group plc
  • 6.3.18 Sun Pharmaceutical Industries Ltd.
  • 6.3.19 Teva Pharmaceutical Industries Ltd.
  • 6.3.20 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space and Unmet-need Assessment